Abstract: A measurement device for process metrology, includes: a number n of sensors, wherein a respective sensor of the number n of sensors is designed to generate associated sensor data such that a total number n of sensor data is generated by way of the number n of sensors; a learning unit, wherein the learning unit is designed to calculate values of a number d of parameters of a hypothesis function based on training data; and a measurement device diagnostic unit, which is designed to calculate a number m of diagnostic values in dependence on the number n of sensor data based on the hypothesis function and the calculated values of the number d of parameters of the hypothesis function.

Abstract: The present invention provides for parenterally administrable live attenuated influenza immune compositions. Methods of using parenterally administrable live attenuated influenza immune compositions to elicit an immune response, and particularly, a protective immune response are also provided.

Abstract: The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K) L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Abstract: The present invention provides for modified Flavivirus such as a modified Zika virus. The modification according to various aspects of the invention results in reduced viral proteins compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region, or the nonstructural protein 3 (NS3) region or both the E and NS3 regions can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flavivirus are used as vaccine compositions to provide a protective immune response.

Abstract: The present disclosure provides methods for treating one or more grains in an ethanol plant or alcohol brewery, methods of drying, cooling, disease control of dried distillers grains with soluble (DDG), barley, or brewer's spent grain (BSG), and a system for treating one or more grains in an ethanol plant or alcohol brewery by these disclosed methods.

Abstract: Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.

Abstract: The invention relates to novel compounds of the formula (I) in which A1, A3, X, R1, R3, R4, R6, R7, R8 and n have the definitions given above, to the use thereof as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for preparation thereof.

Abstract: The present invention relates to deoptimized Yellow Fever viruses and their uses for the treatment of various forms of malignant tumors, and as vaccines against Yellow Fever. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain.

Abstract: The disclosure relates to a transceiver device for communicating between a network protocol controller and a network bus, the transceiver device comprising: transceiver circuitry configured to transmit and receive data on the network bus using a first physical layer protocol; and monitoring circuitry configured to determine a measured property of the network bus, in which the transceiver device is configured to: determine whether the measured property indicates an error condition; and reconfigure the transceiver circuitry to transmit and receive data on the network bus using a second physical layer protocol in response to determining the error condition.

Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.

Abstract: The present invention provides for methods of vaccination and eliciting a IgA immune response and cellular immune response, including T-cell immune response by administering a deoptimized respiratory syncytial virus (RSV).

Abstract: The present disclosure provides methods for treating one or more grains in an ethanol plant or alcohol brewery, methods of drying, cooling, disease control of dried distillers grains with soluble (DDG), barley, or brewer's spent grain (BSG), and a system for treating one or more grains in an ethanol plant or alcohol brewery by these disclosed methods.

Abstract: A biopsy site marker includes a marker element. The marker element includes a base portion and an anchor portion. The anchor portion extends distally from the base portion. The anchor portion includes a plurality of arms. Each arm of the plurality of arms is configured to be responsive to heat to transition from a pre-deployment configuration to a post-deployment configuration. Each arm of the plurality of arms extends outwardly from a longitudinal axis defined by the marker element when the plurality of arms are in the post-deployment configuration.

Abstract: A biopsy site marker includes a marker element. The marker element includes a base portion and an anchor portion. The anchor portion extends from the base portion. The anchor portion includes a plurality of arms. One or more arms of the plurality of arms is configured to be responsive to heat to transition from a pre-deployment configuration to a post-deployment configuration. Each transitioned arm of the plurality of arms extending outwardly from a longitudinal axis defined by the marker element when in the post-deployment configuration.